A CAR-T therapy used to treat cancer managed to reset the immune system and bring three autoimmune diseases into remission in ...
Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in ...
The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the ...
Autoimmune disease occurs from the body’s immune system attacking its healthy cells. Unfortunately, the mechanism that would normally prevent autoimmunity is not present in some individuals. T cells ...
Ahead of World Lupus Day on May 10, new research from the Garvan Institute of Medical Research and UNSW Sydney helps explain ...
Chimeric antigen receptor (CAR) T-cell therapy for cancer led to better outcomes in patients with autoimmune diseases than in those without, a cohort study found. “These findings offered reassurance ...
UCB has struck a deal to acquire Candid Therapeutics for $2 billion upfront, hijacking a planned reverse merger with Rallybio ...
Nkarta's stock soared 690% in six months, buoyed by promising cell therapy technology for cancer and autoimmune diseases. Financially healthy, with a high current ratio and a cash runway extending ...
What if treating autoimmune diseases was as simple as regulating the acidity levels of parts of patients' cells? Genetic screening may have unlocked a path for treating the severe inflammation ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results